Skip to main content
. Author manuscript; available in PMC: 2014 Jun 26.
Published in final edited form as: CNS Neurol Disord Drug Targets. 2013 May 1;12(3):381–391. doi: 10.2174/1871527311312030011

Figure 5. Bcl2 inhibitor significantly inhibits neuroprotection afforded by sevoflurane preconditioning.

Figure 5

A) Effects of sevoflurane preconditioning and Bcl-2 inhibitor (TW-37) on infarct volume. (B) Effects of sevoflurane preconditioning and Bcl-2 inhibitor (TW-37) on neurological scores. Neurological function was tested in rats at 24 and 48 hours after ischemia. (C) Changes in rCBF were not different between groups during ischemia and during reperfusion. Compared with the vehicle group without TW-37 or sevoflurane preconditioning, All data are mean ± SEM, n=10/group, **p<0.01, *p<0.05; compared with the sevoflurane preconditioned group, #p<0.05.